Structural and functional stabilization of bacteriophage particles within the aqueous core of a W/O/W multiple emulsion: A potential biotherapeutic system for the inhalational treatment of bacterial pneumonia

Rios, Alessandra Cândida; Vila, Marta Maria Duarte Carvalho; Lima, Renata de; Fiol, Fernando de Sá Del; Tubino, Matthieu; Teixeira, J. A.; Balcão, Victor M.

doi:10.1016/j.procbio.2017.09.022

Cited by 32 publications

(28 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The molar extinction coefficient of phage φ6 was determined according to [42]. Successive dilutions of phage 6 (10 8 PFU/mL), using different volumes of the phage suspension, were prepared.…”

Section: Methodsmentioning

confidence: 99%

Efficiency of Phage φ6 for Biocontrol of Pseudomonas syringae pv. syringae: An in Vitro Preliminary Study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Pseudomonas syringae is a plant-associated bacterial species that has been divided into more than 60 pathovars, with the Pseudomonas syringae pv. syringae being the main causative agent of diseases in a wide variety of fruit trees. The most common treatments for biocontrol of P. syringae pv. syringae infections has involved copper derivatives and/or antibiotics. However, these treatments should be avoided due to their high toxicity to the environment and promotion of bacterial resistance. Therefore, it is essential to search for new approaches for controlling P. syringae pv. syringae. Phage therapy can be a useful alternative tool to the conventional treatments to control P. syringae pv. syringae infections in plants. In the present study, the efficacy of bacteriophage (or phage) φ6 (a commercially available phage) was evaluated in the control of P. syringae pv. syringae. As the plants are exposed to the natural variability of physical and chemical parameters, the influence of pH, temperature, solar radiation and UV-B irradiation on phage φ6 viability was also evaluated in order to develop an effective phage therapy protocol. The host range analysis revealed that the phage, besides its host (P. syringae pv. syringae), also infects the Pseudomonas syringae pv. actinidiae CRA-FRU 12.54 and P. syringae pv. actinidiae CRA-FRU 14.10 strains, not infecting strains from the other tested species. Both multiplicities of infection (MOIs) tested, 1 and 100, were effective to inactivate the bacterium, but the MOI 1 (maximum reduction of 3.9 log CFU/mL) was more effective than MOI 100 (maximum reduction of 2.6 log CFU/mL). The viability of phage φ6 was mostly affected by exposure to UV-B irradiation (decrease of 7.3 log PFU/mL after 8 h), exposure to solar radiation (maximum reduction of 2.1 PFU/mL after 6 h), and high temperatures (decrease of 8.5 PFU/mL after 6 days at 37 °C, but a decrease of only 2.0 log PFU/mL after 67 days at 15 °C and 25 °C). The host range, high bacterial control and low rates of development of phage-resistant bacterial clones (1.20 × 10−3) suggest that this phage can be used to control P. syringae pv. syringae infections in plants, but also to control infections by P. syringae pv. actinidiae, the causal agent of bacterial canker of kiwifruit. Although the stability of phage φ6 was affected by UV-B and solar radiation, this can be overcome by the application of phage suspensions at the end of the day or at night.

show abstract

Section: Methodsmentioning

confidence: 99%

Efficiency of Phage φ6 for Biocontrol of Pseudomonas syringae pv. syringae: An in Vitro Preliminary Study

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…They will be excreted in the faeces and/or urine, but in the first instance eliminated by the reticulo‐endothelial system (RES) of the spleen. They can be administered in various ways – topically, orally, by nebulization/inhalation, directly into body tissues or intravenously. In addition, patients that are allergic to antibiotics can be treated with phages, usually without adverse effects The production of phages as well as phage dose preparations is a well‐ known biological technology that is based on fermentation processes that are quite similar to the production of vaccines and a range of fine biochemicals. Thanks to the enormous ubiquity and variety of phages in nature, there is far less danger for resistance development than with the current antibiotic (mis)use in the medical and agricultural sectors .…”

Section: Reborn Worldwide and Western Interests And Doubts About Phagmentioning

confidence: 99%

“…In addition, patients that are allergic to antibiotics can be treated with phages, usually without adverse effects. 192 • The production of phages as well as phage dose preparations is a well-known biological technology that is based on fermentation processes that are quite similar to the production of vaccines and a range of fine biochemicals. • Thanks to the enormous ubiquity and variety of phages in nature, there is far less danger for resistance development than with the current antibiotic (mis)use in the medical and agricultural sectors.…”

Section: Phage Therapy Advantages Over Antibiotic Treatmentmentioning

confidence: 99%

A century of bacteriophage research and applications: impacts on biotechnology, health, ecology and the economy!

Vandamme

Mortelmans

2018

J of Chemical Tech & Biotech

View full text Add to dashboard Cite

About a century ago, bacteriophages or phages – viruses that infect bacteria – were discovered and reported in the scientific literature. This review aims at a comprehensive survey of bacteriophage discovery, research and applications since the 1920s, and its impact on molecular biology, biotechnology, health, ecology and the economy. Phage therapy has been proven a valuable asset to deal with pathogenic bacterial infections since the early 1920s, and has been practiced ever since, especially in the former Soviet Union and in Eastern Europe. The Western world remained sceptical and resorted to the widespread use of antibiotics since the 1940s. Now that antibiotic resistance among pathogenic bacteria has spread alarmingly and few really novel antibiotic compounds are in the pipeline, renewed attention is being directed to the use of phages as antibacterial agents in medicine. Because of this renewed interest in phage therapy in the Western world, novel applications with phages are being pursued in the human health, environmental and the agri‐food sectors. This review will focus on (1) the history of early phage use and its successes and problems, (2) the study of phages as important tools in the development of molecular biology and biotechnology, (3) current developments in phage research including the use of phage endolysins for use in antibacterial treatment, (4) phage production systems including undesirable phage contamination of industrial fermentation processes based on bacteria, (5) recent applications in phage therapy and in phage‐based control, and (6) the roles of phages in nature and in the human gut. © 2018 Society of Chemical Industry

show abstract

“…Furthermore, phage particles may undergo denaturation by conformational changes irreversible or reversible. A proposed solution is encapsulation within nanocarriers to become the particles insoluble and protecting them from the digestive and immune system ( Balcão et al, 2014 ; Rios et al, 2018 ). Another critical question is to get the phage particles to the infection site, given that phages do not have pharmacokinetic properties ( Ghosh et al, 2019 ).…”

Section: Alternative Antibacterial Therapiesmentioning

confidence: 99%

Tackling Multidrug Resistance in Streptococci – From Novel Biotherapeutic Strategies to Nanomedicines

et al. 2020

View full text Add to dashboard Cite

The pyogenic streptococci group includes pathogenic species for humans and other animals and has been associated with enduring morbidity and high mortality. The main reason for the treatment failure of streptococcal infections is the increased resistance to antibiotics. In recent years, infectious diseases caused by pyogenic streptococci resistant to multiple antibiotics have been raising with a significant impact to public health and veterinary industry. The rise of antibiotic-resistant streptococci has been associated to diverse mechanisms, such as efflux pumps and modifications of the antimicrobial target. Among streptococci, antibiotic resistance emerges from previously sensitive populations as result of horizontal gene transfer or chromosomal point mutations due to excessive use of antimicrobials. Streptococci strains are also recognized as biofilm producers. The increased resistance of biofilms to antibiotics among streptococci promote persistent infection, which comprise circa 80% of microbial infections in humans. Therefore, to overcome drug resistance, new strategies, including new antibacterial and antibiofilm agents, have been studied. Interestingly, the use of systems based on nanoparticles have been applied to tackle infection and reduce the emergence of drug resistance. Herein, we present a synopsis of mechanisms associated to drug resistance in (pyogenic) streptococci and discuss some innovative strategies as alternative to conventional antibiotics, such as bacteriocins, bacteriophage, and phage lysins, and metal nanoparticles. We shall provide focused discussion on the advantages and limitations of agents considering application, efficacy and safety in the context of impact to the host and evolution of bacterial resistance.

show abstract

Structural and functional stabilization of bacteriophage particles within the aqueous core of a W/O/W multiple emulsion: A potential biotherapeutic system for the inhalational treatment of bacterial pneumonia

Cited by 32 publications

References 43 publications

Efficiency of Phage φ6 for Biocontrol of Pseudomonas syringae pv. syringae: An in Vitro Preliminary Study

Efficiency of Phage φ6 for Biocontrol of Pseudomonas syringae pv. syringae: An in Vitro Preliminary Study

A century of bacteriophage research and applications: impacts on biotechnology, health, ecology and the economy!

Tackling Multidrug Resistance in Streptococci – From Novel Biotherapeutic Strategies to Nanomedicines

Contact Info

Product

Resources

About